Shares of Celldex Therapeutics (CLDX) have gained 5.2% over the past four weeks to close the last trading session at $41.21, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of$69.14 indicates a potential upside of 67.8%. The mean estimate comprises seven short-term price targets with a standard deviation of $20.15. While the lowest estimate of$27 indicates a 34.5% decline from th ...